

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 09/986,234

Confirmation No.: 4995

Applicant : Lazar

Filed : October 22, 2001

TC/A.U. : 1644

Examiner : Ewoldt

Customer No. : 00270



Title : COMPOSITIONS, METHODS, AND KITS RELATING TO RESISTIN

Mail Stop: Amendments  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and §§ 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith.

This Information Disclosure Statement is submitted before the mailing date of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution and is submitted with the appropriate fee of \$180.00 as set forth under 37 CFR § 1.17(p).

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature Lynn Brown-Fischer  
Lynn Brown-FischerDate: May 17, 2006

**REMARKS**

The Examiner is respectfully requested to consider the document(s) identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicant

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
501 Office Center Drive  
Suite 210  
Fort Washington, PA 19034  
Phone: (215) 540-9200  
Fax: (215) 540-5818



UPN-L2066AUSA

PTO/SB/08B (07-05)

Approved for use through 06/30/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	09/986,234
Filing Date	October 22, 2001
First Named Inventor	Lazar
Art Unit	1644
Examiner Name	Ewoldt
Attorney Docket Number	UPN-L2066AUSA

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	EY	MCTERNAN <i>et al.</i> , "Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes", J Clin Endocrinol Metab. 2003 Dec;88(12):6098-106.	
	EZ	YOUN <i>et al.</i> , "Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus", J Clin Endocrinol Metab. 2004 Jan;89(1):150-6.	
	FR	FUJINAMI <i>et al.</i> , "Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes", Clin Chim Acta. 2004 Jan;339(1-2):57-63.	
	FS	AZUMA <i>et al.</i> , "Correlation between serum resistin level and adiposity in obese individuals", Obes Res. 2003 Aug;11(8):997-1001.	
	FT	OSAWA <i>et al.</i> , "The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3", Am J Hum Genet. 2004 Oct;75(4):678-86. Epub 2004 Aug 26.	
	FU	OSAWA <i>et al.</i> , "Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes", Biochem Biophys Res Commun. 2005 Sep 23;335(2):596-602.	
	FV	SMITH <i>et al.</i> , "Serum resistin level in essential hypertension patients with different glucose tolerance", Diabet Med. 2003 Oct;20(10):828-31.	
	FW	ZHANG <i>et al.</i> , "Serum resistin level in essential hypertension patients with different glucose tolerance", Diabet Med. 2003 Oct;20(10):828-31.	
	FX	STEPPAN <i>et al.</i> , "The current biology of resistin", J Intern Med. 2004 Apr;255(4):439-47.	
	FY	AL-HARITHY <i>et al.</i> , "Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus", Ann Saudi Med. 2005 Jul-Aug;25(4):283-7.	
	FZ	MENZAGHI <i>et al.</i> , "Heritability of serum resistin and its genetic correlation with insulin resistance-related features in non-diabetic Caucasians", J Clin Endocrin Metab., May 2, 2006; [e-publication before print].	
	GR	REILLY <i>et al.</i> , "Resistin is an inflammatory marker of atherosclerosis in humans", Circulation. 2005 Feb 22;111(7):932-9. Epub 2005 Feb 14.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

